一个近十年的更新,对抗多克索鲁比诱导的毒性
Sruthi Sritharan1, Nageswaran Sivalingam2
1Department of Biotechnology, School of Bioengineering, College of Engineering and Technology, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamil Nadu, 603203, India.
用多克索鲁比 (dox) 治疗癌症是常见的,但它会导致有毒的副作用. 这篇评论探讨了天然化合物,纳米配方,miRNA和运动,以减轻多克斯诱导的心脏毒性,肝毒性,毒性和神经毒性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 全球癌症发病率正在上升,需要有效的治疗策略.
- 化学疗法,包括多克索鲁比 (dox),仍然是癌症的主要治疗方法.
- 多克索鲁比治疗受到严重副作用的限制,特别是心脏毒性.
研究的目的:
- 审查最近关于减轻多克索鲁比诱导毒性的研究.
- 探索针对心脏毒性,肝毒性,毒性和神经毒性的保护策略.
主要方法:
- 关于多克索鲁比毒性和保护措施的当前科学文献的综述.
- 分析涉及天然化合物,纳米配方,miRNA和体育炼的研究.
- 综合了有关各种干预措施有效性的研究结果.
主要成果:
- 多克索鲁比是一种强大的化疗剂,但具有显著的毒性风险.
- 天然化合物,纳米配方,miRNA和体育炼在减少dox介导的器官损伤方面显示出希望.
- 这些策略有可能改善多克索鲁比的治疗指数.
结论:
- 新兴的策略有效地对抗多克索鲁比诱导的毒性.
- 对这些保护措施的进一步研究可以提高癌症治疗结果.
- 将多克索鲁比与保护性干预相结合可能会提高患者的安全性和治疗效率.
更多相关视频
05:14A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Heart Failure Drugs: Inotropic Agents
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
